Rubicon Research Limited (RUBICON) Operating Income 2025–2026

Name: Rubicon Research Limited (RUBICON) operating income history 2025-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Rubicon Research Limited annual operating income for fiscal 2026 was ₹3.6 billion, an increase of 62.1% from ₹2.2 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

RUBICON Annual Operating Income

Operating Income (annual)	2026-03-31	2025-03-31
Operating Income (EBIT)	₹3.6B	₹2.2B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RUBICON Quarterly Operating Income

Operating Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31
Operating Income (EBIT)	₹1.1B	₹1.1B	₹966M	₹695M	₹628M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Operating Income at Comparable Companies

4503 Operating Income — Astellas Pharma Inc.
4528 Operating Income — Ono Pharmaceutical Co., Ltd.
4536 Operating Income — Santen Pharmaceutical Co., Ltd.
GLAXO Operating Income — GlaxoSmithKline Pharmaceuticals Limited
NOVN Operating Income — Novartis AG

More RUBICON metrics: Revenue · Gross Profit · Net Income · EPS · Free Cash Flow

All RUBICON financial statements → Interactive RUBICON charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.